MRK|Analyst Targets
MRK|Company Info
MRK|Insider Trading
MRK|Fundamentals
MRK|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $2.10 | - | - |
| Q2'26 | $-0.27 | $-0.13 | +52.4% |
| Q1'26 | $2.09 | $-1.28 | -161.2% |
| Q4'25 | $2.03 | $2.04 | +0.5% |
| Q3'25 | $2.35 | $2.58 | +9.9% |
| Q2'25 | $2.03 | $2.13 | +5.0% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $17.5B | - | - |
| Q2'26 | $16.5B | $16.6B | +0.5% |
| Q1'26 | $16.2B | $16.3B | +0.7% |
| Q4'25 | $16.3B | $16.4B | +0.3% |
| Q3'25 | - | $17.3B | - |
| Q2'25 | - | $15.8B | - |
MRK|Monthly Returns
Market Data
MRK Stock Snapshot
- Market cap
- 357.28B
- P/E ratio
- 112.6
- Day range
- $142.15 – $148.16
- News sentiment
- 37/100 · Bearish
- Analyst target
- $158.64 (+7.7%)
- Consensus
- Buy · 38 analysts
Price is in the upper part of its 52-week range, and the momentum read backs that positioning up. Coverage is deep enough that new information gets priced quickly, so surprises tend to be macro rather than fundamental.
Reverse DCF
What growth is priced into MRK?
At today's price, Merck & Co., Inc. needs to grow free cash flow about 11.8% a year for the next 10 years to justify its valuation at a 7.36% cost of capital. Over its actual history it has compounded free cash flow at 4.9% a year, so the market is asking for 6.9 percentage points above its own delivered rate. On that basis MRK looks priced above what its own growth record supports.
- Implied FCF growth
- 11.8%
- Historical FCF CAGR
- 4.9%
- Growth gap
- +6.9 pts
- Verdict
- RICH
- Discount rate (WACC)
- 7.36%
- Beta
- 0.56
Behaviour On Record
What MRK's own history says about today's numbers
- Realized volatility (21d)
- 24.3% 78th pct
- Below its peak
- -9.4%
- vs 200-day average
- +14.4%
- Up days (1y)
- 55%
Merck & Co., Inc. is currently running 24.3% annualised volatility over the last 21 sessions. Measured against MRK's own 13 years of daily returns rather than a market-wide average, that is the 78th percentile — elevated for this stock, against a typical reading of 19.5%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.
MRK is trading -9.4% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -17.3%, and the deepest was -27.8% in 2024. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.
Price sits +14.4% from its 200-day moving average. Against every other day in its history, that gap ranks at the 86th percentile — a wider gap than this stock usually carries. Over the past year MRK closed higher on 55% of sessions, and it is currently 2 sessions into a falling streak.
On October specifically: over 13 years of records, MRK finished the month higher 6 of 13 times, with a median return of -1.4% and an average of -0.8%. Its strongest month historically has been November at +4.1% on average, its weakest September at -1.9%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.
Overnight risk is measurable too: MRK has opened more than 2% away from the prior close in 30 of 3,267 sessions (0.9% of the time), with the largest gaps running +5.3% and -4.2%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.
Across the last 3 dated reports on file, MRK moved an average of 0.8% in the session after earnings, closing higher 2 of those 3 times, with a median move of +0.8% and a largest of +1.1%.
All figures computed from 3,268 daily closes between 2013-10-15 and 2026-10-13, split-adjusted, recomputed daily. Percentiles are against MRK's own 13-year history, not a peer group or index.
Sector Rotation
Is money rotating into or out of MRK's sector?
Merck & Co., Inc. sits in the Health Care sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (leading).
- Sector rank
- #2 of 12
- Sector state
- Leading
- Sector rotation score
- 91
Analyst Rating Changes
Are analysts turning bullish or bearish on MRK?
Citigroup most recently reiterated its rating on Merck & Co., Inc. to Neutral on Oct 12, 2026 with a price target of $145 (from $125). Over the last 90 days, coverage has run 2 upgrades against 1 downgrade, a net bullish lean.
- Latest action
- Citigroup — Neutral
- 90-day upgrades
- 2
- 90-day downgrades
- 1
- Net rating momentum
- +1
Peers & ETF holders
MRK peers & ETF holders
Drug Manufacturers - GeneralMarket cap · today
News Sentiment Analysis
Sentiment gathered from recent headlines
Recent News Coverage
Most recent articles, ranked by recency (click to expand).
Technical Analysis
Real-time indicators across multiple timeframes
| Manager | Trend | Shares Held | % of Co. | Position Value | Filed |
|---|---|---|---|---|---|
| BlackRock, Inc. | ▲ Buy | 226,999,837 | 9.03% | $29.17B | 2026-08-07 |
| Vanguard Group Inc | ▲ Buy | 254,322,763 | 10.12% | $26.77B | 2026-01-29 |
| Wellington Management Group LLP | ▲ Buy | 86,249,283 | 3.43% | $11.08B | 2026-08-14 |
| Geode Capital Management, LLC | ▲ Buy | 60,744,214 | 2.42% | $7.79B | 2026-08-12 |
| Morgan Stanley | ▲ Buy | 48,641,158 | 1.94% | $6.25B | 2026-08-13 |
| FMR LLC (Fidelity) | ▲ Buy | 45,440,355 | 1.81% | $5.84B | 2026-08-13 |
| JPMorgan Chase & Co | ▼ Sell | 43,886,420 | 1.75% | $5.68B | 2026-08-12 |
| Fisher Asset Management, LLC | ▲ Buy | 38,516,263 | 1.53% | $4.95B | 2026-08-04 |
| Norges Bank | ▼ Sell | 36,983,784 | 1.47% | $4.75B | 2026-08-12 |
| Bank of America Corp | ▼ Sell | 30,535,208 | 1.22% | $3.92B | 2026-08-14 |
| Northern Trust Corp | ▼ Sell | 26,275,718 | 1.05% | $3.38B | 2026-08-13 |
| Goldman Sachs Group Inc | ▲ Buy | 22,075,139 | 0.88% | $2.84B | 2026-08-14 |
| Invesco Ltd. | ▼ Sell | 18,611,171 | 0.74% | $2.39B | 2026-08-14 |
| AllianceBernstein L.P. | ▲ Buy | 13,131,942 | 0.52% | $1.58B | 2026-08-14 |
| Harris Associates L P | ▼ Sell | 12,073,109 | 0.48% | $1.55B | 2026-08-14 |
| Wells Fargo & Company | ▲ Buy | 11,658,434 | 0.46% | $1.50B | 2026-08-14 |
| AQR Capital Management LLC | ▼ Sell | 8,134,262 | 0.32% | $1.04B | 2026-08-14 |
| Citigroup Inc | ▲ Buy | 3,614,905 | 0.14% | $464.52M | 2026-08-03 |
| Neuberger Berman Group LLC | ▲ Buy | 3,533,955 | 0.14% | $454.22M | 2026-08-13 |
| D. E. Shaw & Co., Inc. | ▼ Sell | 2,738,023 | 0.11% | $351.84M | 2026-08-14 |
| Janus Henderson Group plc | ▲ Buy | 2,880,199 | 0.11% | $346.47M | 2026-05-18 |
| Adage Capital Partners GP, L.L.C. | ▼ Sell | 2,030,023 | 0.08% | $260.86M | 2026-08-14 |
| Citadel Advisors LLC | ▼ Sell | 1,933,667 | 0.08% | $248.48M | 2026-09-02 |
| Capital Research Global Investors | ▼ Sell | 1,925,013 | 0.08% | $247.36M | 2026-08-12 |
| Prudential Financial Inc | ▼ Sell | 1,913,536 | 0.08% | $245.89M | 2026-08-12 |
| Member | Chamber | State | Type | Amount | Traded | Filed |
|---|---|---|---|---|---|---|
| Maria Elvira Salazar | House | FL27 | ▼ Sell | $1K - $15K | 2026-09-24 | 2026-10-07 |
| Maria Elvira Salazar | House | FL27 | ▲ Buy | $15K - $50K | 2026-08-19 | 2026-09-09 |
| Alan Armstrong | Senate | OK | ▼ Sell | $15K - $50K | 2026-03-27 | 2026-07-21 |
| Josh Gottheimer | House | NJ05 | ▲ Buy | $1K - $15K | 2026-02-04 | 2026-03-16 |
| Gilbert Cisneros | House | CA31 | ▲ Buy | $1K - $15K | 2025-11-18 | 2025-12-15 |
| Donald J. Trump | Senate | - | ▲ Buy | $100K - $250K | 2025-10-31 | 2025-12-19 |
| Valerie Hoyle | House | OR04 | ▼ Sell | $1K - $15K | 2025-09-23 | 2025-10-10 |
| Marjorie Taylor Greene | House | GA14 | ▲ Buy | $1K - $15K | 2025-08-28 | 2025-08-29 |
| Ritchie John Torres | House | NY15 | ▼ Sell | $1K - $15K | 2025-07-11 | 2025-08-20 |
| Gilbert Cisneros | House | CA31 | ▼ Sell | $1K - $15K | 2025-05-30 | 2025-06-06 |
| Gilbert Cisneros | House | CA31 | ▲ Buy | $1K - $15K | 2025-04-29 | 2025-05-06 |
| Rob Bresnahan | House | PA08 | ▲ Buy | $15K - $50K | 2025-04-08 | 2025-05-08 |
| Gilbert Cisneros | House | CA31 | ▼ Sell | $15K - $50K | 2025-03-31 | 2025-04-07 |
| Kelly Louise Morrison | House | MN03 | ▼ Sell | $1K - $15K | 2025-03-20 | 2025-04-11 |
| Bruce Westerman | House | AR04 | ▲ Buy | $1K - $15K | 2025-03-03 | 2025-04-16 |
| Gilbert Cisneros | House | CA31 | ▲ Buy | $15K - $50K | 2025-02-26 | 2025-03-06 |
| Josh Gottheimer | House | NJ05 | ▼ Sell | $15K - $50K | 2025-01-27 | 2025-02-10 |
| Gilbert Cisneros | House | CA31 | ▼ Sell | $1K - $15K | 2025-01-24 | 2025-02-11 |
| Julie Johnson | House | TX32 | ▲ Buy | $1K - $15K | 2025-01-17 | 2025-02-12 |
| Byron Donalds | House | FL19 | ▼ Sell | $1K - $15K | 2025-01-16 | 2025-02-10 |
| Jared Moskowitz | House | FL23 | ▼ Sell | $1K - $15K | 2025-01-15 | 2025-02-10 |
| Valerie Hoyle | House | OR04 | ▲ Buy | $1K - $15K | 2024-10-29 | 2025-09-12 |
| Tommy Tuberville | Senate | AL | ▼ Sell | $1K - $15K | 2023-10-16 | 2023-11-16 |
| Pete Ricketts | Senate | NE | ▼ Sell | $50K - $100K | 2023-09-21 | 2023-10-20 |
| Tommy Tuberville | Senate | AL | ▲ Buy | $1K - $15K | 2022-03-30 | 2022-04-08 |